Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma

Daniel C Osei-Bordom; Gagandeep Sachdeva; Niki Christou

doi:10.3389/fmed.2021.788869

Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma

Front Med (Lausanne). 2022 Jan 14:8:788869. doi: 10.3389/fmed.2021.788869. eCollection 2021.

Authors

Daniel C Osei-Bordom^{1

2

3}, Gagandeep Sachdeva², Niki Christou^{1

4

5}

Affiliations

¹ Department of General Surgery, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, United Kingdom.
² Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
³ National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Centre for Liver and Gastroenterology Research, University of Birmingham, Birmingham, United Kingdom.
⁴ Department of General Surgery, University Hospital of Limoges, Limoges, France.
⁵ EA3842 CAPTuR Laboratory "Cell Activation Control, Tumor Progression and Therapeutic Resistance", Faculty of Medicine, Limoges, France.

Abstract

Pancreatic ductal adenocarcinomas (PDAC) represent one of the deadliest cancers worldwide. Survival is still low due to diagnosis at an advanced stage and resistance to treatment. Herein, we review the main types of liquid biopsy able to help in both prognosis and adaptation of treatments.

Keywords: circulating free DNA (cfDNA); circulating free microRNAs; exosomes; liquid biopsy; pancreatic ductal adenocarcinoma; personalized treatment; prognosis.

Publication types

Review